Adult: 1 g 4 times daily to be taken 1 hour before each meal and at bedtime for up to 8 weeks. Alternatively, 2 g bid to be taken before breakfast and at bedtime for up to 8 weeks. Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product guidelines).
Oral Duodenal ulcer
Adult: For short-term treatment of active cases: 1 g 4 times daily to be taken 1 hour before each meal and at bedtime for 4-8 weeks. Alternatively, 2 g bid to be taken before breakfast and at bedtime for 4-8 weeks. For maintenance treatment to reduce the risk of duodenal ulcer recurrence: 1 g bid to be taken before breakfast and at bedtime. Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product guidelines). Elderly: Initiate at the lower end of the dosage range.
What are the brands available for Sucralfate in Malaysia?
Apo-Sucralfate
Administration
Sucralfate Should be taken on an empty stomach.
Special Precautions
Patient with diabetes mellitus; conditions that may impair swallowing (e.g. recent or long-term intubation, dysphagia, tracheostomy, history of aspiration), or other conditions that may alter gag/cough reflex or reduce oropharyngeal coordination or motility. Patients who are seriously ill, particularly those with delayed gastric emptying or receiving concurrent enteral tube feedings. Renal impairment (especially patients with chronic renal failure or undergoing dialysis). Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Hyperglycaemia (especially in patients with diabetes); increased risk of aluminium accumulation and toxicity such as aluminium osteodystrophy, osteomalacia, and encephalopathy (particularly in patients with renal impairment); bezoar formation (especially in seriously ill patients); aspiration with accompanying respiratory complication. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Constipation, diarrhoea, nausea, vomiting, dry mouth, gastric discomfort, dyspepsia, flatulence. Immune system disorders: Hypersensitivity reactions (e.g. urticaria, dyspnoea, anaphylaxis). Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Headache, dizziness, drowsiness. Psychiatric disorders: Insomnia. Skin and subcutaneous tissue disorders: Rash, pruritus.
Closely monitor blood glucose levels, particularly in diabetic patients.
Drug Interactions
May decrease the extent of absorption of digoxin, quinidine, fluoroquinolone antibiotics (e.g. ciprofloxacin, norfloxacin), tetracycline, ketoconazole, levothyroxine, phenytoin, cimetidine, ranitidine, theophylline, and warfarin; consider dosing interval of at least 2 hours when giving sucralfate with any of these drugs. Antacids may reduce the binding capacity of sucralfate to the gastro-duodenal mucosa, resulting in decreased therapeutic effect; a dosing interval of 30 minutes between sucralfate and antacids is recommended. Concurrent use with other agents containing aluminium (including antacids) may increase the total body burden of aluminium, especially in patients with renal impairment.
Action
Description: Overview: Sucralfate, an anionic sulfated disaccharide, is a cytoprotective and antiulcer agent. Mechanism of Action: Sucralfate binds to positively charged protein exudates on the surface of the ulcer site, forming a viscous ulcer-adherent complex that acts as a local barrier to protect the gastric lining against pepsin, peptic acid and bile salts. It has a greater affinity at the ulcer site, but binding to the normal gastrointestinal mucosa may occur to a minimal extent. Additionally, it may adsorb pepsin and inhibit the acid diffusion across the sucralfate-protein barrier at the ulcer site. Pharmacodynamics: Sucralfate does not appreciably affect gastric acid concentration or output due to a low acid-neutralising capacity (approx 14-16 mEq acid-neutralising capacity per 1 g dose) and a very slow in vitro rate of acid neutralisation. It also does not affect trypsin or pancreatic amylase activity and has little effect on blood coagulation. Onset: 1-2 hours (paste formation and ulcer adhesion). Pharmacokinetics: Absorption: Minimally absorbed from the gastrointestinal tract. Distribution: Locally acts to ulcer sites; unbound in the gastrointestinal tract into aluminium and sucrose octasulfate. Excretion: Mainly via urine (small amounts of sulfated disaccharide).
Chemical Structure
Sucralfate Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 121494085, Sucralfate (USAN:USP:INN:BAN:JAN). https://pubchem.ncbi.nlm.nih.gov/compound/121494085. Accessed Sept. 25, 2025.
Storage
Store between 15-30°C. Do not freeze the oral suspension.
A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
References
Brayfield A, Cadart C (eds). Sucralfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/09/2025.Eficap 500 mg/5 mL Oral Suspension (Caprifarmindo Laboratories PT). MIMS Indonesia. http://www.mims.com/indonesia. Accessed 09/09/2025.Joint Formulary Committee. Sucralfate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/09/2025.Sucralfate Oral Suspension (Major Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/09/2025.Sucralfate Tablet (Chartwell RX, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/09/2025.Sucralfate. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 09/09/2025.Sucralfate. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 09/09/2025.Sucralfate. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 09/09/2025.Ulcefate Tablet, Chewable Tablet and Suspension (Siam Pharmaceutical Co., Ltd). MIMS Thailand. http://www.mims.com/thailand. Accessed 22/09/2025.Viatris Ltd. Carafate 1 g Tablet data sheet 22 November 2022. Medsafe. http://www.medsafe.govt.nz. Accessed 09/09/2025.
Sign Out
Continue with Google